Tirzepatide Linked to Better CV Outcomes Than Semaglutide

A large new study by Cleveland Clinic researchers has found that Tirzepatide is associated with better cardiovascular outcomes than Semaglutide in MASLD patients with obesity and Type 2 diabetes.